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Infectious diseases remain the leading cause of death 
among children and young adults. They account for 
more than 13 million deaths a year with one in two 
deaths occurring in developing countries.Yet, as the 
battle to control known infectious diseases continues, 
new threats have emerged. Currently, researchers are 
challenged by the resurgence of epidemic diseases such 
as cholera, dengue, epidemic meningitis, and hemor- 
rhagic fevers, as well as the devastating development of 
the human immunodeficiency virus (HIV) and acquired 
immunodeficiency syndrome (AIDS) pandemic and 
other new diseases. 
The propagation and transmission of infectious 
agents are favored in today’s world, constituting health 
threats to all countries. The reasons include 
changes in the food industry that facilitate wide- 
spread dissemination of foodborne disease; 
migration and urbanization and the creation of peri- 
urban slums; 
human behavior, including sexual behavior that fos- 
ters sexually transmitted infections (STIs); 
environmental changes, including deforestation and 
changing agricultural practices as well as climate 
change, that have an impact on diseases such as 
malaria, cholera, and Rift Valley fever; 
emergence and spread of antimicrobial resistance, 
now of great public health concern worldwide, as 
many infections become increasingly difficult to treat; 
increasing volume and speed of international travel, 
increasing the potential for rapid international spread 
of disease. 
These factors allow infectious diseases to spread 
rapidly; thus, it is critical to detect any new or unexpected 
outbreak. Effective global surveillance is essential to 
ensure that response is triggered without delay 
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IMPORTANCE OF GLOBAL SURVEILLANCE 
Communicable disease surveillance provides the essential 
information to monitor, evaluate, and model the impact 
of prevention and control activities for endemic com- 
municable and zoonotic diseases; to detect and track epi- 
demic and emerging diseases and other public health 
threats, such as resistance to anti-infective drugs, and to 
geographically locate communicable diseases in coun- 
tries, regions, and globally. At the national level, strength- 
ened and integrated surveillance enables countries to 
identify populations at risk, implement prevention and 
control strategies, detect unusual disease patterns, and 
contain the re-emergence or emergence of communica- 
ble or zoonotic diseases. 
Strong national surveillance is a core building block 
for effective global surveillance systems. Information from 
countries is required to guide international action and 
make the best use of scarce resources. Effective global sur- 
veillance depends on the quality of information from the 
countries. Global networks of laboratories and disease 
surveillance systems monitor specific communicable dis- 
eases and facilitate rapid information exchange on 
unusual disease events. Global and regional networks are 
needed to build the international preparedness and col- 
laboration necessary for a coordinated response. With 
continuing globalization in travel and trade, global epi- 
demic surveillance is essential to ensure international 
public health security The key components of global epi- 
demic surveillance are epidemic intelligence, coordina- 
tion of epidemic response, and epidemic preparedness. 
Successful global epidemic surveillance requires a 
nonpolitical approach and the capacity to facilitate col- 
laboration between diverse partners. The World Health 
Organization (WHO), with its unique global health man- 
date from 191 Member States, is the appropriate organi- 
zation to coordinate this effort. The Organization’s 
multidisciplinary, problem-oriented teams together with 
its epidemic intelligence, preparedness, and response 
activities, have made it the natural focus for requests for 
advice and assistance on epidemic surveillance and 
response worldwide. The WHO recognizes the impor- 
tance of its partners in global epidemic surveillance and 
strives to identify more effective ways of working with 
collaborating institutions. 
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Epidemic Intelligence 
The WHO aims to strengthen national and international 
capacity in surveillance and control of communicable 
diseases, including timely detection and containment of 
outbreaks. An integral part of global epidemic surveil- 
lance, epidemic intelligence (accurate and timely infor- 
mation) about important disease outbreaks that may 
have international implications should be delivered sys- 
tematically and rapidly to key professionals in interna- 
tional public health. This is being achieved through two 
mechanisms: global monitoring networks and outbreak 
verification. 
Global Monitoring Networks 
Unconfirmed reports of rumors of infectious disease 
events around the world are regularly received through 
WHO channels as well as from other sources (including 
nongovernmental organizations, the media and electronic 
discussion groups). Health Canada has developed the elec- 
tronic Global Public Health Intelligence Network 
(GPHIN) in collaboration with the WHO to identify 
potentially high-impact, new, and unusual outbreaks. The 
GPHIN systematically scans the Web, particularly news 
media networks, news wires, and newspapers for out- 
break-related information. The GPHIN provides informa- 
tion on a real-time basis that is used to analyze and assess 
the health risk of international events. The Internet tech- 
nology platform used by the system enables the gather- 
ing of information about public health risks and its 
dissemination to end-users (e.g., WHO) for verification. 
Outbreak Vedftcation 
To investigate and follow-up outbreak reports, the WHO 
established an innovative mechanism, outbreak verifica- 
tion, in early 1997. Outbreak verification aims to improve 
epidemic disease control by actively collecting and veri- 
fying information on reported outbreaks and informing 
key public health professionals about confirmed and 
unconfirmed outbreaks that are of potential international 
public health importance. The outbreak verification sys- 
tem follows the general principles of surveillance: sys- 
tematic collection; collation, analysis, and interpretation 
of data; and dissemination to those who need the infor- 
mation for action. 
When an unconfirmed outbreak report is received, 
the potential public health importance of the event is 
assessed on the basis of available background informa- 
tion, endemicity levels, and details of previous outbreaks. 
The outbreak verification team may seek additional infor- 
mation from other organizations in the field, such as the 
International Red Cross, Medecins sans Front&es, and 
Medical Emergency Relief International. 
Whenever the outbreak verification team invokes a 
verification process, assistance to the affected country is 
offered. Examples of such assistance include initial inves- 
tigation of the outbreak on site, supply of essential ma- 
terials to the outbreak site, transport of laboratory 
specimens from the field to appropriate diagnostic facil- 
ities, organization of vaccination programs, training of 
field staff as part of outbreak control measures, or deploy- 
ment of field teams for disease control. 
Over 500 outbreaks have been investigated in the 
past 2 years. Cholera, viral hemorrhagic fevers, and 
meningococcal meningitis comprised half of these events. 
Other outbreaks included plague, anthrax, viral encephal- 
itides, dysentery, influenza, and relapsing fever. Virtually 
all countries experienced at least one outbreak. It is 
planned that this process will, in future, be applied 
directly at the regional level. 
Epidemic Response 
When dealing with epidemics, the response of the inter- 
national community needs to be coordinated. Three cri- 
teria are used to determine whether an international 
response is required: 
1. Humanitarian: Does the country have the capacity 
to respond to an epidemic? 
2. International spread: Does the disease have the poten- 
tial to spread beyond national borders? 
3. Travel and trade: Is there a risk that the epidemic 
may result in inappropriate international travel and 
trade restrictions? 
The WHO plays an active role in the coordination of 
international epidemic response, and the number of 
requests to the WHO for technical and material support 
has increased significantly. Response can be in the form 
of investigating, verifying and disseminating information, 
coordinating response efforts in the field, or direct inter- 
vention in the field. 
Examples of recent outbreaks during which WHO 
teams were in the field include: viral hemorrhagic fever 
in Afghanistan (2000); cholera in Madagascar (2000); 
Lassa fever and shigellosis in Sierra Leone (2000); Mar- 
burg virus infection in the Democratic Republic of the 
Congo (1999-2000); cholera in Somalia (1999-2000); 
influenza in Afghanistan (1999); relapsing fever in south- 
ern Sudan (1999); Rift Valley fever in Mauritania 
(199% 1999); avian influenza (H5Nl) in Hong Kong, Spe- 
cial Administrative Region of China (1997-1998); and 
monkeypox in the Democratic Republic of the Congo 
(1996-1997). 
Surveillance and response projects for emergency sit- 
uations were undertaken in East Timor, Kosovo, and south- 
ern Sudan. Follow-up activities were then implemented 
in the areas of epidemiology training, laboratory strength- 
ening, and information system development. Thus, an epi- 
demic represents one of many entry points for the WHO 
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to become more deeply involved with an affected coun- 
try, in the areas of epidemic preparedness and the devel- 
opment of more effective epidemic response. 
Epidemic Preparedness 
The WHO works to improve global, regional, and national 
preparedness for epidemics by 
. establishing global epidemic surveillance standards, 
. creating networks of partners for preparedness and 
rapid response, 
. strengthening laboratory capacity and laboratory net- 
works, 
. training in field epidemiology, and 
. assessing and strengthening national surveillance 
systems. 
Effective partnerships to strengthen surveillance and pre- 
paredness lead to an effective, timely response. 
Global Surveillance Networks 
Partnerships 
Cholera 
Nearly 120 countries have reported indigenous cases of 
cholera to the WHO since 1991, and nearly half of those 
countries have reported cholera for at least 5 of the past 
8 years. Surveillance efforts show that the number of 
reported cases increased nearly 100% in 1998 compared 
to 1997, on all continents; thus, cholera is a recurring, 
growing problem in many areas. 
In 1991, the WHO Global Task Force on Cholera Con- 
trol was established to develop a more coordinated, more 
action-oriented approach to epidemic preparedness and 
control of this disease. Together with its partners on the 
task force, the WHO has developed an effective strategy 
to control cholera outbreaks and currently is considering 
the benefits of using oral vaccines in some specific pub 
lit health settings. 
Dengue-Deugue Hemorrbagk Fever 
The geographic distribution of dengue has greatly 
expanded, and the number of cases has increased dra- 
matically in the past 30 years. It is now endemic in more 
than 100 countries in Asia and Latin America and threat- 
ens the health of about 40% of the world’s population 
(2.5 billion people), particularly in tropical and subtrop- 
ical regions and predominantly in urban and periurban 
areas. Over 1.2 million cases were reported to the WHO 
in 1998, the greatest number ever for a single year. There 
are an estimated 50 million infections annually, including 
400,000 cases of dengue hemorrhagic fever (DHP), a 
potentially lethal complication first recognized during 
the 1950s and currently a leading cause of childhood 
mortality in several Asian countries. The increase of 
dengue and DHF is attributable to uncontrolled popula- 
tion growth and urbanization in the absence of appro- 
priate water management, to the global spread of dengue 
strains via travel and trade, and to the erosion of vector 
control programs. 
Controlling dengue epidemics once they become 
established is difficult. Therefore, it is important to imple- 
ment control measures when an increase in disease activ- 
ity is first detected. This requires an effective disease 
surveillance program and intervention plan. Proactive sur- 
veillance systems that facilitate collection, referral, and 
testing of blood samples, and reporting and analysis of 
results, also can be used to predict outbreaks. 
The WHO is embarking on new initiatives to 
strengthen global surveillance for dengue and response 
to outbreaks, to improve case management, and to 
develop an effective and safe dengue vaccine. 
Influenza 
Since 1948, the WHO has developed and coordinated a 
global network for surveillance of influenza. The net- 
work gathers worldwide data on influenza activity. 
Detailed annual analysis of the circulating strains of 
influenza viruses provides the information on which 
WHO formulates recommendations to vaccine manu- 
facturers for the composition of influenza vaccines for 
the following season in both the northern and southern 
hemispheres. 
This global surveillance system comprises over 110 
national influenza centers and four WHO collaborating 
centers where detailed analyses are carried out. An elec- 
tronic database, FluNet, has been set up to allow coun- 
tries to enter data on local virus isolates and to obtain 
information from other countries. Another product of 
the influenza program is the “Influenza Pandemic Pre- 
paredness Plan,” which was published this year and is 
available on the Internet. The outbreak-response capac- 
ity on the influenza network was tested and shown to 
be effective in Hong Kong, Special Administrative 
Region of China, during the 1997-1998 avian influenza 
episode. 
Human Immunodeficiency Virus and 
Acquired ImmunodefMency Syndrome 
The United Nations (UN) AIDS-WHO Working Group on 
Global HIV-AIDS and STI surveillance was established in 
1997 to coordinate activities in this area. The group meets 
regularly to review HIV estimates. The activities carried 
out by the WHO are designed to develop national and 
international surveillance infrastructures, to ensure that 
information is available at global and local levels, to direct 
and evaluate prevention and control activities, and to 
stimulate research on new approaches to surveillance, 
prevention, and control. 
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Regional meetings are held with national HIV-AIDS 
epidemiologists and program managers to review sur- 
veillance activities, discuss improvements, analyze the 
present estimation methodologies, and draft plans of 
action and recommendations for future activities. A work- 
shop on surveillance in hard-tereach areas has been orga- 
nized in collaboration with UNAIDS and the Robert Koch 
Institute (Berlin, Germany). 
Letshmaniasis-Human Immunodeficiency 
Virus Co-infectton 
Leishmaniasis has been a long standing problem, affect- 
ing 350 million people in 88 countries around the 
world. A relatively recent development has been the 
emergence of leishmaniasis-HIV co-infection as a grow- 
ing public health problem, resulting from the spread of 
leishmaniasis from rural to urban areas and the spread 
of HIV outward from the cities. The WHO, in partner- 
ship with UNAIDS, developed a new surveillance net- 
work to face this growing challenge, now involving 28 
surveillance centers around the world. An electronic 
database was created and data analysis has been 
improved by mapping the cases using a geographic 
information system. Guidelines for the treatment of vis- 
ceral leishmaniasis-HIV co-infections were produced and 
widely distributed. 
Aftican T?ypanosomiasis (Sleeping Sickness) 
Sleeping sickness was well-controlled earlier this century 
but has re-emerged over the past 30 years. It strikes 
remote rural areas south of the Sahara where health sys- 
tems are either weak or nonexistent. Its spread is fur- 
thered by socioeconomic factors that prevent the 
establishment of public health initiatives (e.g., political 
instability, wars, and poverty). 
Confronted with this resurgence, and facing a crisis 
in drug supply for this forgotten disease, the WHO has 
taken the lead in mobilizing and coordinating the activ- 
ities of endemic countries and a wide range of partners. 
Surveillance demonstrated a pressing need for a contin- 
uing supply of drugs, and the WHO is working with the 
pharmaceutical industry, which has a unique role in com- 
bating this disease. An effective public-private sector part- 
meningitis by ensuring the availability and rational dis- 
tribution of emergency supplies of meningococcal 
serogroup A and C vaccine to countries experiencing 
epidemic meningococcal meningitis. As well as vaccine, 
the ICG ensures supplies of safe injection materials and 
antibiotic. 
In addition to its central role in enabling an effec- 
tive response to epidemics to be mounted, the ICG is 
now a working partnership that also deals with pre- 
paredness for epidemics and coordination of material and 
technical international support. The WHO provides the 
secretariat for the group, whose work is overseen by a 
subgroup of key international agencies: United Nations 
International Children’s Emergency Fund (UNICEF), 
WHO, International Federation of the Red Cross and Red 
Crescent Societies (IFRC), and MCdecins sans Front&-es. 
The severe epidemic in Sudan, with 33,216 cases and 
2386 deaths, dominated the 1998-1999 meningitis season 
in Africa, and the ICG was involved in providing techni- 
cal and material support to the government as well as 
supplies for mass immunization campaigns and treatment 
of cases. In 2000, the most severely affected countries 
have been Niger, Chad, Central African Republic, and 
Cameroon, with a continuing problem also in Southern 
Sudan. 
Resistance to Anti-infectiue Drugs 
Another approach to global networking is to take advan- 
tage of ongoing programs outside the WHO. Other net- 
works exist, and they can be harnessed to contribute to 
a global resource. An example of this is antimicrobial- 
resistance monitoring, for which many programs exist 
throughout the world. 
In 1999, the WHO established a new team to lead 
and expand its work on the surveillance and contain- 
ment of resistance to anti-infectives. One of the strate- 
gies adopted by the group is to link the many existing 
antimicrobial-resistance (AR) monitoring networks to 
form a global network. Information on resistant organ- 
isms is now brought together in an electronic database, 
the AR InfoBank, which is now accessible on the Internet. 
Zoonoses and Foodborne Pathogens 
nership will ensure the availability and affordability of 
drugs to treat this orphan disease, which is invariably 
Many infectious agents that cause outbreaks of human 
fatal without treatment. 
disease are zoonotic pathogens transmitted from animals 
or from food of animal origin. There is a need for closer 
The International Coordtnattng Growp on Vaccine links between medical and veterinary public health 
Provtston for Epidemic Meningttis Control authorities to recognize and control such outbreaks more 
effectively. The WHO is currently launching a new ini- 
The International Coordinating Group (ICG) on vaccine tiative on food safety, in which surveillance of foodborne 
provision for epidemic meningitis control was set up in pathogens and outbreaks is an important component. 
January 1997 in response to a crisis in vaccine supply The consequences of the use of antibiotics as growth 
for the control of severe epidemics of meningitis in promoters in livestock are being evaluated as part of this 
Africa. The ICG strives to reduce the burden of epidemic effort, with a view to monitoring the emergence of 
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resistant organisms that threaten human health, and to 
advocate for the prudent use of antibiotics in animal 
husbandry. 
Rabies 
Rabies, one of the major zoonotic diseases, remains an 
important but underreported health problem in many 
developing countries. The WHO global rabies surveil- 
lance initiative (World Survey of Rabies) has been 
extended, and a Web version (RABNET) prepared. The 
database currently provides annual incidence and other 
data (e.g., status of surveillance, types of vaccines used) 
for over 140 countries for 1998. World surveys of human 
and animal rabies were carried out for 1997 and 1998, 
with data received from 137 countries. 
The WHO is developing the “WHO Rabies Vaccine 
Initiative 2000.” This initiative seeks to identify ways to 
overcome the current lack of affordable and safe rabies 
vaccines for humans in many rabies-infected areas and 
to prevent many of the estimated 60,000 annual deaths 
due to rabies. 
Global Network of World Health 
Organization Collaborating Centers 
Over 200 WHO collaborating centers worldwide deal 
with surveillance and response to communicable dis- 
eases. They comprise specialized laboratories or institu- 
tions with expertise in infectious diseases and cover a 
wide range of speciality areas. Many of the centers work 
on a particular disease or pathogen (e.g., meningococcal 
meningitis, influenza, or rabies), whereas others cover a 
wider range of diseases or pathogens that fall within a 
group (e.g., arboviruses), or cover areas such as anti- 
microbial resistance. The WHO is able to call upon experts 
in these centers of expertise all over the world, which are 
now linked electronically in an interactive network. 
The centers regularly receive and analyze specimens 
and epidemiologic information from the country or coun- 
tries that they serve. They work closely with the WHO 
to investigate, confirm, and control outbreaks of com- 
municable diseases (e.g., during recent outbreaks of hem- 
orrhagic fevers in Democratic Republic of the Congo, 
Kenya, and Sudan or of Nipah virus infection in Malaysia). 
They support global surveillance networks (influenza) 
and facilitate information exchange for global monitor- 
ing and control (antimicrobial resistance). Thus, these 
collaborating centers play a crucial role in the imple- 
mentation of WHO activities. 
International Health Regulations 
Since 1948, the WHO has been responsible for the admin- 
istration of the International Health Regulations (IHR), 
the only binding international public health legislation, 
which was ratified by its 190 Member States. The goal of 
the IHR is to ensure maximum security against the inter- 
national spread of diseases with minimum interference 
with world traffic and trade. These regulations are 
intended to strengthen the use of epidemiologic princi- 
ples as applied internationally and to detect, reduce, or 
eliminate the sources from which infection spreads. They 
encourage epidemiologic activities at the national level 
so that there is little risk that an infection can spread 
from its country of origin to another country. 
The current regulations, which date from 1969, apply 
only to cholera, plague, and yellow fever. Given the cur- 
rent trends in the epidemiology of communicable dis- 
eases and emerging disease threats, however, many other 
diseases can create international disturbance. To adapt 
to these new developments and to strengthen the global 
alert to outbreaks of potential international health impor- 
tance, the regulations are currently being revised. It is 
proposed that under the revised regulations, any outbreak 
of urgent international importance will be notifiable. 
Importance of Surveillance at the National Level 
Currently, most surveillance activities are supported and 
managed by a variety of vertical disease control programs. 
Some are effective and linked to well-supported pro- 
grams, whereas others have lost momentum, are poorly 
maintained, or have virtually collapsed. In some cases the 
surveillance function is far removed from any corre- 
sponding action such as disease control efforts, outbreak 
response, health resource allocation, or national health 
policy. Much of the work of the WHO in this area con- 
sists in helping countries to assess and strengthen their 
surveillance systems by encouraging a multidisease 
approach to make the best use of personnel and other 
available resources. 
Integrated Disease Surveillance and Response 
Effective communicable disease control relies on effective 
surveillance and response systems. Information on com- 
municable diseases is a key part of public health deci- 
sion-making in all countries. It is essential for priority 
setting, planning, resource mobilization and allocation, 
prediction and early detection of epidemics, and moni- 
toring and evaluation of disease prevention and control 
programs. Disease surveillance is a critical component of 
health systems, providing essential information to ensure 
optimal health care delivery and cost-effective health 
strategies. 
An integrated approach to communicable disease sur- 
veillance envisages all surveillance activities in a country 
as a common public service that carries out many func- 
tions, using similar structures, processes, and personnel. 
The surveillance activities that are well developed in one 
area may act as driving forces for strengthening other 
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surveillance activities, offering possible synergies and 
common resources. 
The activities of the WHO are focussed on countries. 
Comprehensive assessments of national surveillance sys- 
tems are carried out with the objective of building capac- 
ity within countries. The process brings together key 
decision-makers, strengthens communications networks, 
and fosters complete ownership of the process by the 
countries concerned. Nationals from both the public and 
private sectors are involved, as well as a range of partners, 
agencies, and institutions. National assessments have been 
carried out jointly with country staff of the United States 
Centers for Disease Control and Prevention (CDC) and 
United States Agency for International Development 
(USAID). The epidemiologic and laboratory capacity of a 
country is assessed in the light of current needs as 
defined by the priority diseases. After the field visits, a 
national plan of action is developed with short-, medium-, 
and long-term objectives, to address problems identified 
during the assessment, maximize synergies, and seek 
opportunities for integration. This is the starting point 
for a long-term obligation to which governments and 
communities must be committed. The success of national 
surveillance depends on political and financial support 
from the highest level. It is anticipated that an additional 
seven countries will conduct national surveillance sys- 
tems assessments in 2000. 
An integrated disease surveillance strategy for Africa 
was developed and endorsed by all Member States of 
the region, and activities using an integrated approach 
are now also under way in the other WHO-member 
regions. National surveillance plans are in preparation 
in a number of countries, including Egypt, Ethiopia, 
India, Lesotho, Madagascar, Malawi, and United Repub- 
lic of Tanzania. 
Standard-setting and Data Collection and Analysis 
The work of the WHO in this area includes the prepara- 
tion of surveillance guidelines, the elaboration of com- 
mon terminology, and the setting of standards, in 
consultation with experts. In 1999, the second edition of 
WHO-recommended surveillance standards (covering 
over 40 diseases and syndromes) was finalized and pub- 
lished. A protocol for the assessment of national surveil- 
lance systems is being revised and field-tested. 
A surveillance report prepared in 1999 brings 
together global information on several priority commu- 
nicable diseases, notably data on cholera, plague, and yel- 
low fever reported to the WHO between 1950 and 1999 
under the International Health Regulations. 
Geographic Information Systems 
Spatial analysis and mapping in epidemiology have a 
long history, but until recently their use in public health 
has been limited. Maps have been either created man- 
ually, or in research institutes using expensive computer 
equipment. However, recent advances in geographic 
information and mapping technologies have created 
new opportunities for public health administrators to 
enhance their planning, analysis, and monitoring capa- 
bilities. The late 1990s have seen a significant expan- 
sion in information and mapping technology, including 
the development of desktop mapping software, new 
programming tools for customization of mapping prod- 
ucts and increasing connectivity to information high- 
ways such as the Web. 
In a WHO-UNICEF joint program, a database man- 
agement and mapping system, named HealthMap, has 
been developed and customized for public health appli- 
cations at country, regional, and global levels. The sys- 
tem contains a standardized georeferenced database of 
country, regional, district and subdistrict boundary 
maps, rivers, roads, villages, and health and social infra- 
structures. Originally tested in West Africa, the system 
was extended in 1999 to cover an additional 10 coun- 
tries: Cambodia, Egypt, Islamic Republic of Iran, Lao 
People’s Democratic Republic, Myanmar, Thailand, 
Tunisia, Turkey, Vietnam, and Zimbabwe. HealthMap is 
now an important part of the WHO’s Roll Back Malaria 
initiative. 
CONCLUSION 
The WHO strives to ensure global public health security 
against infectious diseases through surveillance of infec- 
tious diseases and prompt and appropriate response to 
outbreaks. Through its global public health mandate, the 
Organization can play a special role in fostering effective 
links and partnerships to create an effective worldwide 
network, making the best use of expertise and resources, 
in the interest of world health. 
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